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Background: In children, idiopathic nephrotic syndrome (INS) is primarily treated using 
corticosteroids. When remission is not achieved, the coadministration of potent immunosuppres-
sant therapy becomes imperative. Cyclosporine A (CsA) is reportedly associated with a higher 
incidence of remission in comparison with other immunosuppressive agents.
Methods: The present study investigated the response of combination therapy using CsA 
and prednisolone in 30 Tunisian children with idiopathic steroid-resistant nephrotic syndrome 
(ISRNS). Renal histopathology was compatible with focal segmental glomerular sclerosis 
(FSGS) in 15 children, minimal change disease (MCD) in nine children, and diffuses mesangiale 
proliferation (DMP) in six children.
Results: The therapy protocol produced a complete remission of proteinuria in 15 patients 
(50%) and a partial remission in nine patients (30%). Six patients (20%) showed no response 
to therapy. Progression to end stage renal disease occurred in five CsA-resistant children and 
in four CsA-responsive patients. CsA-related nephrotoxicity was detected by renal biopsy 
in one patient.
Conclusions: CsA remains the primary cytotoxic treatment for childhood steroid-resistant 
nephrotic syndrome. Its use in combination with corticosteroids provides optimum efficiency 
without high risk of nephrotoxicity.
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Introduction
The management of steroid-resistant nephrotic syndrome (SRNS) remains a 
  clinical problem. Several treatment modalities have been tested, including high-
dose   corticosteroids, cyclophosphamide, cyclosporine A (CsA), and more recently, 
tacrolimus. Optimal combinations of medications with least toxicity remain to be 
determined. Treatment with a combination of oral prednisolone and oral CsA may 
lead to remission in a significant proportion of children. However, the long-term use 
of CsA exposes the patient to nephrotoxicity and requires clinical, biological, and 
histopathological monitoring.
Previously, many authors, in particular Niaudet,1 have reported the beneficial effect 
of a combination of oral prednisolone and oral CsA. This finding was confirmed by a 
recent multicenter study2 which demonstrated that CsA had a significantly higher rate 
of response than did cyclophosphamide pulse therapy. The present study was therefore 
performed to evaluate the effectiveness and safety of CsA in Tunisian children with 






This retrospective study included all children with ISRNS 
who received the combined oral idiopathic (Neoral® or 
Equoral®) and oral prednisone for the period between 
  January 2002 and December 2008. Inclusion criteria were: 
(1) steroid resistance, either primary or secondary; (2) age 
at onset of nephrotic syndrome: .1 year and ,14 years; 
(3) minimal follow-up period: 1 year; (4) diagnosis of idio-
pathic nephrotic syndrome since January 2002. Exclusion 
criteria were: (1) nephrotic syndrome underlying second-
ary causes; (2) patients with family history of SRNS; (3) 
congenital or syndromic forms of SRNS; (4) patients with 
creatinine clearance of less than 50 mL/min per 1.73 m².
Definitions
Nephrotic syndrome was defined as proteinuria .50 mg/kg 
per 24 hours; or protein/creatinine .3 mg/kg associated with 
hypoproteinemia ,60 g/L and hypoalbuminemia ,30 g/L.
Steroid-resistance, either primary or secondary, was 
defined as a failure to achieve resolution of clinical and labora-
tory features of nephrotic syndrome after four weeks of daily 
prednisolone therapy (60 mg/m²) followed by three   intravenous 
pulses of methyl-prednisolone at a dose of 1 g/1.73 m².
Complete remission was defined as a proteinuria level of 
less than 10 mg/kg per day. The remission was considered as 
partial when proteinuria was between 10 and 50 mg/kg per 
day, with a serum albumin greater than 30 g/L.
A relapse of nephrotic syndrome in patients who achieved 
complete or partial remission was defined as the reappearance 
of proteinuria greater than 50 mg/kg per day.
histopathology
Renal biopsy was performed after a diagnosis of steroid 
  resistance, or if the patient’s age at onset of idiopathic 
  nephrotic syndrome (INS) was more than 12 years. Repeat 
biopsy was performed if therapy toxicity was suspected. 
Biopsy specimens were processed using standard procedures 
that included hematoxylin-eosin, periodic acid-Schiff, and 
green Masson straining of formalin-included pieces. Immu-
nofluorescence of frozen samples was carried out with a panel 
of antiserum protein antibodies against the   immunoglobulins 
A, M and G (IgA, IgM, and IgG) and the 3rd and 4th 
  complement components (C3 and C4).
Therapeutic protocol
For our patients with ISRN, we adopted the protocol   treatment 
established by the French Society of Pediatric Nephrol-
ogy.1 CsA was given to all patients at an oral initial dose of 
150–200 mg/m² body surface area per day (not exceeding 
200 mg/m² per day), in two equal doses. The   dosage was 
adjusted to obtain trough concentrations between 100 and 
150 ng/mL, as measured by the monoclonal antibody radioim-
munoassay on whole blood before the morning dose. CsA dos-
age was reduced by 20% if there was a decrease in creatinine 
clearance (calculated by the Schwartz formula) of more than 
25%. Prednisone was administered at a single dose of 30 mg/
m² per day during the first month and then at the same dose, 
but on alternate days, for five months.
The therapeutic response was assessed four months 
after starting the treatment protocol. In patients who had 
not achieved complete or partial remission, the therapeutic 
regimen was stopped. If a remission had been obtained, 
the dose of prednisone was digressed and stopped within 
three months, and that of CsA was tapered and stopped 
within the following three months (the provided duration of 
treatment was 12 months).
When relapse occurred during the prednisone tapering 
phase, the patients were again treated with the initial com-
bined therapy of CsA and prednisone. In cases of relapse 
during the CsA tapering phase, only CsA was re-introduced 
at the initial dosage for one month, and eventually predni-
sone was added when remission was not achieved. When a 
relapse occurred later than one month after the CsA therapy 
had been stopped, steroid responsiveness was tested again 
with oral prednisone therapy.
When CsA was impossible to continue, second line 
intravenous cyclophosphamide or Mycophenolate mofetil 
(MMF) was used.
Follow-up
All children were followed up every two weeks in the first 
month, and every month thereafter. The following measure-
ments and laboratory tests were performed at each visit: 
body height and weight; blood pressure; complete blood cell 
count; serum creatinine; electrophoresis of proteins; serum 
cyclosporine level; and proteinuria.
statistical analysis
We are interested mainly in the therapeutic response to 
CsA according to histological type and the fact that steroid 
resistance is initial or secondary. The statistical analysis was 
performed using the StatView software 5.0 (SAS Institute 
Inc., Cary, NC). Categorical variables were compared using 
the unpaired Student’s t-test. Nominal variables were com-
pared using chi square. A statistically significant difference 
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Results
Thirty children with SRINS were analyzed during the study 
period. There were 19 males and 11 females. The mean age 
at the start of treatment was 8 years (range 1.4 to 14 years). 
Nineteen patients (63%) were initially steroid-resistant and 
eleven patients (37%) were secondary steroid-resistant. The 
first renal histopathology showed features suggestive of 
minimal change disease in nine patients (30%), focal seg-
mental glomerular sclerosis (FSGS) in 15 patients (50%), 
and mesangioproliferative glomerulonephritis in six patients 
(20%). During the first two weeks of treatment, the mean oral 
dose of CsA was 165 mg/m² per day and the mean whole 
blood trough level was 141 ng/mL.
Six patients (20%) showed no response to therapy. The 
use of cyclophosphamide and MMF did not give a satisfac-
tory response. All these patients have since progressed to 
chronic renal failure, with the exception of one patient, 
who presented a remission under inhibitors of angiotensin-
  converting enzyme, which still maintains normal renal func-
tion after a decline of five years.
Fifteen patients (50%) achieved complete remission 
and partial remission was achieved in nine patients (30%). 
The overall response (complete or partial remission), 
regardless of pathological types, was 80%. The remis-
sion was achieved during the first month of treatment in 
25% (6/24) of patients; during the second month in 33% 
of patients (8/24); during the third month in 33% (8/24) 
of patients; and during the forth month in 8% of patients 
(2/24).
Also, the response to treatment was analysed according 
to various parameters: age, sex, initially or secondary steroid 
resistance, and pathological type (Table 1). We did not find 
a statistically significant relationship between the different 
parameters tested and the response to CsA.
At the sixth month of treatment, there was no   significant 
rate of hypertension. One patient required the use of 
angiotensin-converting enzyme inhibitors. Six patients 
were already hypertensive before starting treatment. The 
creatinine clearance according to the Schwartz formula 
was not significantly different compared to the baseline 
creatinine clearance. At month 24, patients with complete 
remission maintained a normal creatinine level. For patients 
with partial remission, the outcome was marked by impaired 
renal function in four patients, 9, 12, 13, and 15 months 
respectively after the onset of treatment. Renal biopsy was 
performed in all cases and showed pathological findings 
compatible with natural course of SRNS in three patients and 
intense interstitial fibrosis in one case. In this last patient, 
CsA was replaced by MMF, which permeated to maintain a 
partial remission and a rapid improvement of renal function. 
With the exclusion of this patient, the other three patients 
progressed to end-stage renal disease occurring between the 
16th and 36th months.
Cosmetic adverse events were observed with   varying pro-
portions: hypertrichosis in 60% of cases; gingival   hypertrophy 
in 27%; and tremors in 11.5%. The first   side-effect to appear 
was the tremor followed by hypertrichosis.
Among the 15 patients with complete remission, eight 
patients maintained this response even after discontinuation 
of the therapeutic protocol and five patients experienced a 
relapse six months after the start of treatment. Two patients 
had a relapse three and five months, respectively, after the 
  stopping of CsA. Corticosteroid therapy alone was tried in 
both but only one patient had a good response. The other 
patient received the same protocol again for two years.
Discussion
In childhood ISRNS, CsA remains the first-line ther-
apy. The mechanism by which CsA induces remission 
of   proteinuria remains incompletely elucidated. The 
  interleukin-2-inhibiting action may not explain all effects 
of CsA.3 A non-immunologic mechanism is quite plausi-
ble.4 Used alone, CsA has allowed a complete remission 
in a small proportion of patients;5 however, since its use 
combined with prednisone, it has offered a better thera-
peutic response. In the collaborative study of Niaudet et al 
using CsA in combination with prednisone, approximately 
50% of patients had a remission which was complete in 
most cases.1 The dosage of prednisone used in combination 
with CsA varies according to studies. Gregory et al6 used 
Table 1 Therapeutic response to cyclosporine A (csA) according 







Mean age in months  
(range)
86.0 (17–168) 86.5 (41–168) 0.981
sex M 16 (84%) 3 (16%)
F 8 (73%) 3 (27%) 0.641
steroid 
resistance
Initially 14 (74%) 5 (26%) 0.372
secondary 10 (91%) 1 (9%)
histopathology McD 7 (78%) 2 (22%) 0.966
Fsgs 12 (80%) 3 (20%)
PMD 5 (83%) 1 (17%)
Abbreviations: M, male; F, female; csA, cyclosporine A; McD, minimal change 
disease;  Fsgs,  focal  segmental  glomerular  sclerosis;  PMD,  diffuses  mesangiale 





an alternate day prednisone dose of 2 mg/kg in his study 
and obtained a remission rate of 86%. However, when 
using a low dose of prednisone, the therapeutic response 
appears to be lower, as reported by Hymes.7 Also, the use 
of intravenous methyl-prednisolone (MTP) associated to 
CsA may not improve the rate of remission. The idea of 
combining CsA, MTP and prednisone appears to offer 
a better therapeutic approach. Waldo8 and later Ehrich9 
reported, in two retrospective studies of children with 
focal segmental hyalinosis and treated with cyclo-MPT-
prednisone, high rates of complete remission ranging 
between 84 and 90%. Hamasaki,2 in his retrospective study, 
used methylprednisolone pulse therapy in addition to CsA 
and prednisone in patients with FSGS. The results of this 
protocol   treatment were encouraging with a response rate 
of around 85.7%. However, the number of patients reported 
in this study was small (seven) and so valid conclusions 
cannot be drawn. In summary, all these studies have sug-
gested that CsA improves steroid sensitivity in steroid-
resistant nephrotic children and recommend the use of 
combination cyclosporine-prednisone in the management 
of steroid-resistant nephrotic syndrome.
The initial dose of CsA has been variably expressed 
either in mg/kg or mg/m² body surface area. The trough 
level recommended by most authors varies from 100 to 
150 ng/mL during the first three months, and between 60 and 
100 ng/mL later, when remission is achieved.1,2,10 The major-
ity of CsA-responsive patients experience remission during 
the first three months of treatment. In the present study, most 
patients who attained partial or complete remission did so 
after three months of treatment.
The duration of treatment with CsA is difficult to predict. 
It depends on the therapeutic response obtained and tolerance. 
The risk of cyclo-dependence and frequent relapse is real, 
leading to prolonged treatment for several years.11 In patients 
who fail to show any reduction of proteinuria at the end of 
six months of treatment, no significant benefit is expected 
later. A difficult question is when to abandon CsA treatment 
and declare a patient as a non-responder to this drug. A trial 
period of six months is commonly used.12
Considering the histological type, Hymes7 found that 
the overall response to CsA is very similar in the three 
histological types. However, the rate of complete remis-
sion is frequently observed during the ‘minimal change 
disease’ (MCD) condition. The partial remission is more 
frequent in the FSGS and ‘diffuses mesangiale proliferation’ 
(DMP) conditions. In our study, there was no significant 
difference in response to CsA, regardless of the   histology 
(P = 0.212): 78% for MCD and 80%–83% for FSGS and 
DPM. On the other hand, Niaudet1 obtained a poorer 
response in patients with FSGS compared with those with 
MCD (51.5% vs 40%). Hamasaki et al2 administered the 
bolus MTP in addition to CsA and prednisone, to maximize 
the rate of remission in patients with FSGS and achieved a 
remission rate of 85.7%.
The nephrotoxicity is the main side-effect of CsA, which 
may contribute to the progression towards chronic renal 
failure.13 It must be detected by routine pathological study 
after two years of treatment, even in patients who maintain 
a normal creatinine clearance.14 To evaluate the nephro-
toxicity in children with ISRNS, Hamasaki2 performed a 
systematic renal biopsy after 12–24 months of treatment. 
Among 26 patients, he noted only one with CsA-related 
  nephrotoxicity. This low rate of nephrotoxicity was attrib-
uted to an adequate monitoring of the CsA dosage. Similar 
findings have been objectified in our study, although we did 
achieve a renal biopsy in only a small proportion of patients. 
The nephrotoxicity related to CsA does not appear to be 
higher than that related to tacrolimus. In a recent comparative 
study, we did not identify a difference in terms of efficacy 
or   nephrotoxicity, but cosmetic side-effects and hyperten-
sion were rarely observed with tacrolimus.15 Nephrotoxicity 
related to CsA appears to be dose-dependent. A low-dose 
CsA, administered for a period exceeding four years, seems 
safe, as evidenced by the study of Ghiggeri et al16 involving 
children with FSGS. Moreover, nephrotoxicity related to 
CsA may be reduced by several agents, such as vitamin E 
and corticosteroids, which have a suppressive effect on CsA-
induced apoptosis.17,18 When CsA is impossible to continue 
because of its nephrotoxicity, the switch may be provided 
by the MMF.19 This agent is able to maintain remission with 
rapid improvement of renal function. Moreover, if nephrotic 
syndrome persists under CsA therapy, there are no effective 
therapeutic alternatives besides the current tests involving 
rituximab whose results are so far promising.20 This new 
therapeutic approach must however undergo testing in 
  randomised prospective clinical trials.
Conclusion
Presently, a combination therapy composed of CsA and pred-
nisone appears to be the most promising strategy to adopt in 
childhood ISRNS. However, the long-term CsA therapy may 
be complicated by renal tubulointerstitial fibrosis leading to 
the use of other non-nephrotoxic immunosuppressive agents. 
MMF in this situation is a good therapeutic alternative, able to 
maintain the therapeutic response without nephrotoxicity.International Journal of Nephrology and Renovascular Disease
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